恒指新贵药明生物(02269.HK)小米(01810.HK)涨5%-8% 惟阿里续软 染蓝大热倒灶美团倒升
3只恒指新贵及被剔出3只成份股今早个别发展,小米集团-W(01810.HK)表现最好,股价四连涨,最高见16.66元,现造16.56元,急涨8%,成交增至1.93亿股,涉资31.51亿元。药明生物(02269.HK)重越10天线(166元),最高见171.5元,现造169.5元,回升5%;但阿里巴巴-SW(09988.HK)连续两天受压,最低见241.2元,现造245.2元,续跌0.6%。此外,被剔出恒指成份股的信置(00083.HK)及旺旺(00151.HK)逆跌逾2%,前者失守10天及20天线,最低见9.18元,现造9.26元,回吐3%;後者曾一举失守50天、10天及20天线(5.72元/5.8元/5.83元),最低见5.69元,现造5.73元,续吐2.5%;但神华(01088.HK)反覆重越10天及20天线(12.9元及13.05元),高低见13.12元/12.62元,现造13.06元,反覆回升1.5%。
「染蓝」大热倒灶只获纳入国企成份股的美团点评-W(03690.HK)曾失守10天线(21.8.7元),急吐4.9%低见209元获承接,掉头高见221.8元,现造221.4元,倒升0.7%。此外,被剔出国企成份股的中信证券(06030.HK)随A股(涨5.8%曾高见33.28元人民币)续升5.1%报19.3元,股价重越10天及20天线,同被剔出国企的国药(01099.HK)续升2.1%报19.18元,股价重越10天线(18.98元),但被剔出国企成份股的比亚迪(01211.HK)反覆吐1.2%报72.6元。
恒生指数公司上周五收市後宣布季度检讨结果,恒指指成分股新纳入小米、药明生物及阿里巴巴-SW,以代替被剔出信置、旺旺及神华,成份股总数维持50只。另外,恒生中国企业指数新纳入小米、美团点评及阿里巴巴,取代初剔出国药、比亚迪及中信证券,成份股总数目维持50只。上述所有变动9月7日(星期一)起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.